David A. Siegel Aeterna Zentaris Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.17 - $0.37 $3,876 - $8,436	-22,800 Reduced 59.22%	15,700 $3,000
Q1 2022 May 16, 2022	SELL	$0.33 - $0.42 $1,947 - $2,478	-5,900 Reduced 13.29%	38,500 $14,000
Q4 2021 Feb 14, 2022	BUY	$0.36 - $0.77 $15,984 - $34,188	44,400 New	44,400 $16,000
Q1 2021 May 17, 2021	SELL	$0.51 - $3.34 $94,605 - $619,570	-185,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$0.3 - $0.44 $8,640 - $12,672	28,800 Added 18.38%	185,500 $79,000
Q3 2020 Nov 16, 2020	BUY	$0.34 - $0.55 $53,278 - $86,185	156,700 New	156,700 $55,000
Q4 2019 Feb 14, 2020	SELL	$0.77 - $1.08 $8,932 - $12,528	-11,600 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.0 - $2.97 $100 - $297	-100 Reduced 0.85%	11,600 $12,000
Q2 2019 Aug 14, 2019	BUY	$2.04 - $5.43 $23,868 - $63,531	11,700 New	11,700 $35,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.